{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:26:33Z","timestamp":1791491193898,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11096-020-01171-5","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T07:02:58Z","timestamp":1603263778000},"page":"737-742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-life data of survival and reasons for discontinuation of biological disease-modifying drugs \u2018in\u2019 rheumatoid arthritis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-2210","authenticated-orcid":false,"given":"Ana Paula Monteiro","family":"Gomides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleandro Pires","family":"de Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz Vargas","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoel Barros","family":"B\u00e9rtolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Louzada","family":"J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina Dalva Neubarth","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e3o Cezar","family":"Radominski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda B.","family":"Resende Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Rossi","family":"Bonfiglioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"de F\u00e1tima Lobato da Cunha Sauma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e2nio Alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claiton Viegas","family":"Brenol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia Maria Henrique","family":"da Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldo da Rocha Castelar","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"1171_CR1","first-page":"721","volume":"35","author":"F Ferro","year":"2017","unstructured":"Ferro F, Elefante E, Luciano N, Talarico R, Todoerti M. One year in review 2017: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2017;35:721\u201334.","journal-title":"Clin Exp Rheumatol"},{"key":"1171_CR2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","volume":"43","author":"VP Nell","year":"2004","unstructured":"Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43:906\u201314.","journal-title":"Rheumatology"},{"key":"1171_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","volume":"4","author":"P Rein","year":"2017","unstructured":"Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017;4:247\u201361.","journal-title":"Rheumatol Ther"},{"key":"1171_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"1171_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1171_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/art.38323","volume":"66","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol. 2014;66:775\u201382.","journal-title":"Arthritis Rheumatol"},{"key":"1171_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.reuma.2017.04.007","volume":"15","author":"N Alvarez Rivas","year":"2017","unstructured":"Alvarez Rivas N, Vazquez Rodriguez TR, Miranda Filloy JA, Garcia-Porrua C, Sanchez-Andrade Fernandez A. Long-term survival of subcutaneous anti-tumor necrosis factor biological drugs administered between 2008 and 2012 in a cohort of rheumatoid arthritis patients. Reumatol Clin. 2017;15:54.","journal-title":"Reumatol Clin"},{"key":"1171_CR8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1080\/14397595.2018.1537556","volume":"29","author":"M Kondo","year":"2019","unstructured":"Kondo M, Yamada H. Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14\u00a0year-retrospective study from a rheumatology clinic in Japan. Mod Rheumatol. 2019;29:928.","journal-title":"Mod Rheumatol"},{"issue":"Suppl 2","key":"1171_CR9","first-page":"ii30","volume":"62","author":"M Flendrie","year":"2003","unstructured":"Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003;62(Suppl 2):ii30\u20133.","journal-title":"Ann Rheum Dis"},{"key":"1171_CR10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3899\/jrheum.111125","volume":"39","author":"F Iannone","year":"2012","unstructured":"Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, et al. Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol. 2012;39:1179\u201384.","journal-title":"J Rheumatol"},{"key":"1171_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jbspin.2016.02.028","volume":"84","author":"Divonne M de La Forest","year":"2017","unstructured":"de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers. Joint Bone Spine. 2017;84:133\u201340.","journal-title":"Joint Bone Spine"},{"key":"1171_CR12","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1136\/annrheumdis-2011-200838","volume":"71","author":"R Sakai","year":"2012","unstructured":"Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis. 2012;71:1820\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1171_CR13","first-page":"523","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55:523\u201334.","journal-title":"Rheumatology (Oxford)"},{"key":"1171_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.101142","volume":"38","author":"JA Markenson","year":"2011","unstructured":"Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol. 2011;38:1273\u201381.","journal-title":"J Rheumatol"},{"key":"1171_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","volume":"1173","author":"A Marchesoni","year":"2009","unstructured":"Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837\u201346.","journal-title":"Ann N Y Acad Sci"},{"key":"1171_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pupt.2014.01.005","volume":"27","author":"S Saturni","year":"2014","unstructured":"Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, et al. Randomized controlled trials and real life studies approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27:129\u201338.","journal-title":"Pulm Pharmacol Ther"},{"key":"1171_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.31887\/DCNS.2011.13.2\/hmoeller","volume":"13","author":"HJ Moller","year":"2011","unstructured":"Moller HJ. Effectiveness studies: advantages and disadvantages. Dialogues Clin Neurosci. 2011;13:199\u2013207.","journal-title":"Dialogues Clin Neurosci"},{"key":"1171_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s42358-018-0017-9","volume":"58","author":"Castelar-Pinheiro G da Rocha","year":"2018","unstructured":"da Rocha Castelar-Pinheiro G, Vargas-Santos AB, de Albuquerque CP, B\u00e9rtolo MB, J\u00fanior PL, Giorgi RDN, et al. The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil. Adv Rheumatol. 2018;58:9.","journal-title":"Adv Rheumatol"},{"key":"1171_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"1171_CR20","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO , et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"1171_CR21","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:S100\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"1171_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/0470114754","volume-title":"An introduction to categorical data analysis","author":"A Agresti","year":"2007","unstructured":"Agresti A. An introduction to categorical data analysis. 2nd ed. New York: Wiley; 2007.","edition":"2"},{"key":"1171_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10067-016-3424-5","volume":"36","author":"Y An","year":"2017","unstructured":"An Y, Liu T, He D, Wu L, Li J, Liu Y, et al. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study. Clin Rheumatol. 2017;36:35\u201343.","journal-title":"Clin Rheumatol"},{"key":"1171_CR24","first-page":"1380","volume":"77","author":"D Choquette","year":"2018","unstructured":"Choquette D, Rahman P, Chow A, Faraawi R, Olszynski W, Rampakakis E, et al. AB0436 Consolidated long-term safety of infliximab in inflammatory arthritis from a prospective, observational registry. Ann Rheum Dis. 2018;77:1380\u20131.","journal-title":"Ann Rheum Dis"},{"key":"1171_CR25","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.24463","volume":"61","author":"SM Du Pan","year":"2009","unstructured":"Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61:560\u20138.","journal-title":"Arthritis Rheum"},{"key":"1171_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","volume":"74","author":"M Neovius","year":"2015","unstructured":"Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74:354\u201360.","journal-title":"Ann Rheum Dis"},{"key":"1171_CR27","doi-asserted-by":"publisher","first-page":"e0194130","DOI":"10.1371\/journal.pone.0194130","volume":"13","author":"K Ebina","year":"2018","unstructured":"Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis-The ANSWER cohort study. PLoS ONE. 2018;13:e0194130.","journal-title":"PLoS ONE"},{"key":"1171_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22\u201332.","journal-title":"Arthritis Rheum"},{"key":"1171_CR29","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.22788","volume":"68","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, et al. Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res (Hoboken). 2016;68:432\u20139.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01171-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-020-01171-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01171-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:04:31Z","timestamp":1634774671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-020-01171-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01171-5","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"APMG: Has received personal support and consulting fees from Pfizer and Janssen. CPA: Has received personal fees and\/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB. ABVS: Has received support for international medical events from AbbVie and Janssen. MBB: Has participated in clinical and\/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer. PLJ: Has received support for international congresses from Bristol-Myers Squibb and UCB and consulting fees from Pfizer. RDNG: Has received consulting fees, speaking fees and support for international congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli Lilly, AbbVie, Abbott and EMS. SCR: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB. MFBRG: No financial disclosures. KRB: Has received speaking fees and support for international congresses from Roche, Pfizer, Bristol-Myers Squibb, Abbvie and Janssen. MFLCS: No financial disclosures. IAP: Has received consulting fees, speaking fees and support for international congresses from Roche, Pfizer, UCB Pharma, Eli Lilly, Abbvie and Janssen. CVB: Has participated in clinical and\/or experimental studies related to this work and sponsored by AbbVie, BMS, Janssen, Pfizer and Roche; has received personal or institutional support from AbbVie, BMS, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer and Roche. LMHM: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB. GRCP: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Pfizer, Sanofi Genzyme and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}